BIOBank, a French leader in bone allografts, and Spineart are proud to announce a strategic partnership aimed at improving access to high-quality allogenic bone substitutes for spine surgeons in France and Switzerland.
A Synergistic Approach to Spinal Fusion
Under the agreement, Spineart will promote BIOBank’s portfolio, with a focus on BIOBank Synergy® – a moldable natural putty designed for bone fusion – leveraging its well-established commercial spine network, ensuring a wide market coverage in both countries.
Spineart’s fusion products and BIOBank’s biologic solutions complement each other by offering spine surgeons a complete, integrated approach to spinal fusion combining advanced implants with high-quality allografts that support effective bone healing.
Strengthening European Leadership
Already distributing BIOBank products in Spain, Spineart is now expanding its biologics offering to France and Switzerland. As a major player in the French spine market, Spineart is the ideal partner to deliver surgeons the BioBank products.
Alexandre Tepas, CEO, BIOBank said: “We are thrilled to join forces with Spineart. Their proven expertise and extensive network make them the ideal partner to accelerate the adoption of our bone allografts in spine surgery. Together, we will not only expand into key markets, but also support surgeons in their practice and, most importantly, improve outcomes for patients.”
Jerome Trividic, CEO, Spineart added: “We are expanding our European leadership by integrating BIOBank’s allografts, sourced from living donors, into Spineart’s procedural spine surgery offering. This partnership strengthens our ability to provide surgeons with a complete solution for each intervention, combining cutting-edge implants and biologics to support reproducible workflows and deliver optimized patient outcomes.”
About BIOBank
Founded in 1999, BIOBank is a leading French human tissue bank specializing in production allogenic bone grafts for orthopedic, spinal, dental and maxillofacial applications. BIOBank masters its value chain: from the collection from living donors, to the preparation of BIOBank allografts using Supercrit® technology, and their distribution on multiple European markets (Switzerland via its affiliate NEUTROMEDICS, Spain, Poland and the United Kingdom via its partners). BIOBank’s product portfolio includes geometrical shapes, powder, and granules as well as BIOBank Synergy® to address a broad range of surgical needs.
About Spineart
Spineart is a global fast-growing company in spine surgery innovation, dedicated to accelerating the adoption of cutting-edge technologies for surgeons and hospitals worldwide for the benefit of their patients. Renowned for its commitment to Quality, Innovation, and Simplicity, Spineart continues to push the boundaries of spinal surgery with its comprehensive portfolio of procedural solutions and digital technologies. Spineart was awarded the “Prix de l’Economie Genevoise 2022” for its contribution to technological and scientific innovations, commercial activities, job creations and ESG principles.
Please visit www.spineart.com and follow on LinkedIn. For media inquiries or further information, please contact press@spineart.com